Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio that was acquired last year, and ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

AbbVie (NYSE:ABBV) has recently seen promising developments with the release of favorable final results from the MIRASOL ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE� (mirvetuximab soravtansine-gynx) in women with folate ...